glp·helper
glphelper.com/semaglutide/pennsylvania/bethlehem
GLP-1 receptor agonistFDA-approved December 2017 (Ozempic) · June 2021 (Wegovy)Rx · Subcutaneous injection (weekly) · oral tablet (Rybelsus, daily) · Once weekly (injectable)

Semaglutide® providers &
prescriptions in Bethlehem, PA

Verified Semaglutide providers in Bethlehem, PA. Checked against the NPI registry, sorted by waitlist, not by who pays us.[7]

city providers
29
as of today
median wait
8d
first visit
telehealth
71%
of providers
cash range
$25 to $1,150
monthly
§ 02Provider directory: Pennsylvania
30 of 30 shown

Find a Semaglutide provider in Pennsylvania.

Every entry is checked against the NPI registry and the Pennsylvania medical board. Listings are ordered by current waitlist. The provider who can see you fastest appears first. We do not accept payment for placement.

Filter →
Type
Provider
City
Waitlist
Insurance
Browse by Pennsylvania city · /semaglutide/pennsylvania/{city}
§ 03Getting Semaglutide in Bethlehem
30 providers · Bethlehem, PA

How to get Semaglutide in Bethlehem.

30 GLP-1 prescribers and 6 local resource types are on record for Bethlehem, plus 3 nearby towns in the directory.

Prescribers in Bethlehem
30 prescribers
30 GLP-1 prescribers in Bethlehem, most listed as Family Medicine (11), Internal Medicine, Endocrinology, Diabetes & Metabolism (10) and Internal Medicine (5). Any Pennsylvania-licensed physician, nurse practitioner, or PA can prescribe Semaglutide, over video or in person. The nearest towns on record are Allentown (38 providers), Norristown (27 providers) and Reading (33 providers).
Around the prescription in Bethlehem
6 listed nearby
51 dietitians, 6 gyms, 6 fitness clubs, 6 trainers, 6 physiotherapists and 6 places to move are on record near Bethlehem.
Medicaid (weight loss)
Diabetes only
As of April 2026, Pennsylvania Medicaid covers GLP-1s for diabetes but not for weight loss. Employer and private plans can still cover them; that is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Pennsylvania’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

The molecule in Ozempic, Rybelsus, and Wegovy. The brands differ in approved use and maximum dose.

Semaglutide is a once-weekly GLP-1 receptor agonist sold under three brand names by Novo Nordisk: Ozempic and Rybelsus for type 2 diabetes, and Wegovy for chronic weight management. It mimics a gut hormone that signals satiety to the brain and slows gastric emptying. The injectable forms share the same molecule; only the approved indication and maximum dose differ.[2][3]

In the STEP-1 obesity trial, adults without diabetes taking Wegovy (semaglutide 2.4 mg) lost a mean of 14.9% of body weight at 68 weeks versus 2.4% with placebo. In the SELECT trial, semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease but without diabetes.[1]

At a glanceMultiple (brand-specific)
Generic name
semaglutide
Drug class
GLP-1 receptor agonist
Manufacturer
Novo Nordisk
FDA approved
December 2017 (Ozempic) · June 2021 (Wegovy)
Approved use
Type 2 diabetes (Ozempic/Rybelsus) · chronic weight management (Wegovy)
Off-label use
Use outside the approved brand/indication is off-label
Administration
Subcutaneous injection (weekly) · oral tablet (Rybelsus, daily) · Once weekly (injectable)
Available doses
0.25 mg · 0.5 mg · 1 mg · 1.7 mg · 2.4 mg
Half-life
≈ 7 days
Pregnancy
Discontinue ≥ 2 months before a planned pregnancy

Community health · CDC

Weight & metabolic health in Bethlehem

Bethlehem, Pennsylvania has a population of 75,781 people. The adult obesity rate in Bethlehem is an age-adjusted estimate of 36.4%, 2.2 percentage points above the Pennsylvania state rate of 34.2%. Diagnosed diabetes reaches 11.3% of adults in Bethlehem. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 26.9% of adults in Bethlehem.

of Bethlehem adults have obesity
36.4%
diagnosed diabetes
11.3%
no regular physical activity
26.9%

Age-adjusted estimates for Bethlehem, community figures, not individual risk. CDC PLACES, 2024 release.

Estimate your weight lossHRT and weight-loss medication
§ 05Support around Semaglutide in Bethlehem
6 dietitians

The prescription is one part. Here is the rest, in Bethlehem.

Trials of semaglutide paired the drug with diet counseling and regular activity. Every name below is a real listing near Bethlehem, PA, ordered as the registry lists them, never by who pays us.

Registered dietitians

A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.

Lori Ahdieh, RD, LDN
RD
Registered dietitian
2855 Schoenersville Rd
Call 484-884-2964NPI 1053860403
Nancy Amici, RD, LDN
RD
Registered dietitian · Metabolic
2545 Schoenersville Rd
Call 484-884-2964NPI 1396293262
Judity Barkanic, R.D
RD
Registered dietitian
801 Ostrum St
Call 610-954-4166NPI 1477792943
Andrea Barnes, MS, RD, LDN, FAND
RD
Registered dietitian
187 Main St Ste 300
Call 610-421-4849NPI 1912340142
Leslie Billowitch, RD, LDN
RD
Registered dietitian
2855 Schoenersville Rd
Call 610-807-5654NPI 1689123101
Maryelizabeth Ciliberti, R.D
RD
Registered dietitian
801 Ostrum St
Call 610-954-4166NPI 1770722241

Gyms near you

A gym gives you the regular movement that keeps muscle while the weight comes off.

Planet Fitness
GYM
4.3 on Google · 544 reviews
1740 Stefko Blvd
Website
Powerhouse Gym
GYM
4.6 on Google · 385 reviews
2134 W Union Blvd
Website
Maxx Fitness Clubzz Saucon Valley
GYM
3.3 on Google · 324 reviews
3691 PA-378
Website
Steel Fitness Riverport
GYM
3.4 on Google · 243 reviews
15 W 2nd St
Website
St. Luke's Fitness & Sports Performance Center - Bethlehem
GYM
3.9 on Google · 128 reviews
77 S Commerce Way
Website
Muscle Inc. Gym
GYM
4.9 on Google · 115 reviews
1856 Stefko Blvd
Website
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize the STEP weight-management program, the SUSTAIN diabetes program, and the SELECT cardiovascular outcomes trial. Figures are means at each trial's primary endpoint.

STEP-1 randomized 1,961 adults with overweight or obesity (without diabetes) to semaglutide 2.4 mg or placebo for 68 weeks. Mean weight change was −14.9% with semaglutide versus −2.4% with placebo; 86% of treated patients lost ≥5% of body weight.[2]
STEP / SELECT endpoint table2.4 mg / 68 wk
Mean weight change (Wegovy 2.4 mg)
−14.9%
STEP-1, 68 wk vs −2.4% placebo[2]
Patients losing ≥5% body weight
86%
STEP-1, 2.4 mg[2]
Major adverse cardiac events
−20%
SELECT, HR 0.80[3]
HbA1c reduction (T2D)
−1.4 to −1.8%
SUSTAIN program[4]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average semaglutide weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Boxed warning: risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
20 to 44%
mild
Most common; dose-dependent, usually eases after titration
Diarrhea
20 to 30%
mild
More frequent during dose escalation
Vomiting
16 to 24%
mild
Reduced by slower titration
Constipation
20 to 24%
mild
Abdominal pain
10%
moderate
Pancreatitis
<0.3%
serious
Discontinue if acute pancreatitis is suspected
Gallbladder disease
1.6 to 2.6%
serious
Cholelithiasis risk rises with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated with MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Cash, Wegovy (no insurance)
$1,300 to $1,400
per month
Brand-name retail average[6]
Cash, Ozempic (no insurance)
$950 to $1,150
per month
Brand-name retail average[6]
Commercial insurance (T2D)
$25 to $250
per month copay
Usually covered for diabetes with prior authorization
Commercial insurance (weight)
Often denied
Wegovy is on-label but frequently requires PA and is denied
Medicare Part D
$0 to $100
per month
T2D covered; weight-loss indication not covered by law[5]
Manufacturer savings card
as low as $0 to $25
per month
Commercial insurance only; eligibility limits apply
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Semaglutide providers in Pennsylvania

NPI-verified Semaglutide (semaglutide) prescribers and clinics, ordered by availability, never by who pays us.

Semaglutide in other states

Find NPI-verified Semaglutide (semaglutide) doctors, clinics, and pharmacies in the states we cover, ordered by availability, never by who pays us.

Related GLP-1 research
§ 09Frequently asked: Semaglutide in Pennsylvania

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

Yes. Semaglutide is the active molecule in all three Novo Nordisk products. Ozempic and Rybelsus are approved for type 2 diabetes; Wegovy is approved for chronic weight management at a higher maximum dose (2.4 mg/week). Insurers treat the brands as separate drugs.[1]